PPARG and Other metabolic disease: As previously indicated, PPARγ is a key regulator of fat metabolism and therefore, targeting this nuclear receptor can be useful in metabolic disorders such as lipodystrophy, dyslipidaemia and insulin resistance, which are all commonly associated with cART57.